Tulobuterol Uses, Dosage, Side Effects & Safety | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Tulobuterol
Therapeutic Class: Bronchodilator
Subclass: Long-acting β2-adrenergic agonist (LABA)
Speciality: Pulmonology
Schedule (India): Schedule H
Route(s): Transdermal
Formulations Available in India:
- Transdermal patch: 0.5 mg (paediatric)
- Transdermal patch: 1 mg
- Transdermal patch: 2 mg
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ 1. Bronchial Asthma (Maintenance Therapy)
Important: Only as adjunctive therapy with inhaled corticosteroids. NOT for acute symptom relief or rescue therapy.
| Parameter | Recommendation |
|
Starting dose
|
2 mg patch applied once daily (evening application preferred) |
|
Titration
|
Usually not required |
|
Usual maintenance dose
|
2 mg patch once daily |
|
Maximum dose
|
2 mg/day |
Clinical Notes:
- Apply patch to clean, dry, hairless area of trunk or upper arm
- Rotate application sites daily to minimise skin irritation
- Remove old patch before applying new one
- Do not cut patches
- Ensure patient has separate rescue inhaler (SABA) for acute symptoms
▶ 2. Chronic Obstructive Pulmonary Disease (COPD) — Maintenance Bronchodilation
| Parameter | Recommendation |
|
Starting dose
|
2 mg patch once daily |
|
Titration
|
Not required |
|
Usual maintenance dose
|
2 mg once daily |
|
Maximum dose
|
2 mg/day |
Clinical Notes:
- Beneficial for reducing morning dyspnoea and nocturnal symptoms
- Use as part of comprehensive COPD management including smoking cessation
- Avoid in patients with significant arrhythmia or uncontrolled hypertension
- Not a substitute for inhaled LABA/LAMA combinations in moderate-severe COPD
Secondary Indications — Adults Only (Off-label)
None documented in Indian practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶ Bronchial Asthma (Maintenance Therapy)
| Age Group | Starting Dose | Titration | Usual Maintenance | Maximum Dose |
|
6–11 years
|
1 mg patch once daily | Not required | 1 mg once daily | 1 mg/day |
|
≥12 years (Adolescents)
|
2 mg patch once daily | Not required | 2 mg once daily | 2 mg/day |
Clinical Notes:
- Use only under paediatric pulmonologist supervision
- Must be used with inhaled corticosteroids — never as monotherapy
- Apply patch in evening; remove after 24 hours
- Rotate application site daily
- Ensure child has separate SABA rescue inhaler
- Useful alternative when child cannot use inhaler devices properly
Secondary Indications — Paediatrics (Off-label)
Not applicable.
Safety Monitoring (Paediatric):
- Monitor heart rate before and after initiation
- Observe for tremor, restlessness, or sleep disturbances
- Assess skin at application site for irritation or hypersensitivity
- Periodic assessment of growth if on concurrent inhaled corticosteroids
Age Restrictions:
- Not recommended below 6 years of age due to limited safety data
- Use below 6 years only under specialist supervision with documented justification
RENAL ADJUSTMENT
| Renal Function | Recommendation |
| Mild–Moderate impairment | No dose adjustment required |
| Severe impairment (eGFR <30 mL/min) | Limited data; use with caution; monitor for systemic β2-agonist effects |
| Haemodialysis | No specific data; monitor clinically |
HEPATIC ADJUSTMENT
| Child-Pugh Class | Score | Recommendation |
|
Class A (Mild)
|
5–6 points | No dose adjustment required |
|
Class B (Moderate)
|
7–9 points | Use with caution; monitor for β2-agonist adverse effects |
|
Class C (Severe)
|
10–15 points | Avoid use unless benefit clearly outweighs risk; increased systemic exposure possible |
CONTRAINDICATIONS
- Known hypersensitivity to tulobuterol or patch excipients
- Severe cardiac arrhythmias (tachyarrhythmias, atrial fibrillation with rapid ventricular response)
- Uncontrolled hyperthyroidism
- Concurrent use with other long-acting β2-agonists (LABA)
CAUTIONS
- Cardiovascular disease (ischaemic heart disease, hypertension, arrhythmias)
- Diabetes mellitus — may cause hyperglycaemia
- Hyperthyroidism — may exacerbate symptoms
- Hypokalaemia or predisposition to electrolyte disturbances
- Concurrent use with other sympathomimetics
- Seizure disorders
- Skin conditions at potential application sites
- Not for acute asthma attacks or acute bronchospasm — ensure patient has rescue SABA
- LABA monotherapy (without ICS) associated with increased asthma mortality — always use with inhaled corticosteroid
PREGNANCY
| Aspect | Details |
|
Overall safety
|
Limited human data; animal studies suggest potential β2-agonist related risks |
|
When to use
|
Only if clearly needed and benefit outweighs potential risk; specialist guidance required |
|
Preferred alternatives
|
Inhaled salmeterol or formoterol combined with ICS (more established safety data) |
|
Monitoring required
|
Maternal: heart rate, blood pressure. Fetal: heart rate monitoring if chronic use in late pregnancy |
LACTATION
| Aspect | Details |
|
Compatibility
|
Likely compatible — low systemic bioavailability from transdermal route |
|
Expected levels in milk
|
Low (minimal systemic absorption expected) |
|
Preferred alternatives
|
Inhaled LABAs (salmeterol, formoterol) if available |
|
Infant monitoring
|
Observe for irritability, sleep disturbances, tachycardia (unlikely with transdermal use) |
ELDERLY
| Aspect | Recommendation |
|
Starting dose
|
2 mg patch once daily (same as adult dose) |
|
Titration
|
Not required; slower onset of clinical response may occur |
|
Extra risks
|
Increased sensitivity to tremor, tachycardia, electrolyte disturbances; underlying cardiovascular disease may be exacerbated |
|
Monitoring
|
Heart rate, blood pressure, serum potassium if on concurrent diuretics or corticosteroids |
|
Practical tips
|
Transdermal route advantageous in elderly with poor inhaler technique; ensure adequate skin integrity at application site |
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect/Risk | Management |
|
Non-selective β-blockers (propranolol, carvedilol)
|
Antagonise bronchodilator effect; may precipitate bronchospasm | Avoid combination; if β-blocker essential, use cardioselective agent (bisoprolol, metoprolol) |
|
MAO inhibitors (phenelzine, tranylcypromine, linezolid)
|
Potentiate cardiovascular effects; risk of hypertension, arrhythmias | Avoid combination or use with extreme caution |
|
Tricyclic antidepressants (amitriptyline, imipramine)
|
Potentiate cardiovascular effects | Use with caution; monitor heart rate and rhythm |
|
QT-prolonging drugs (haloperidol, amiodarone, ondansetron)
|
Additive risk of arrhythmias, especially with hypokalaemia | Monitor ECG; correct electrolytes before and during treatment |
|
Other LABAs (salmeterol, formoterol)
|
Additive β2-agonist effects; increased risk of cardiovascular adverse effects | Avoid concurrent use of multiple LABAs |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect/Risk | Management |
|
Loop diuretics (furosemide)
|
Additive hypokalaemia risk | Monitor serum potassium; supplement if necessary |
|
Thiazide diuretics
|
Additive hypokalaemia risk | Monitor potassium levels |
|
Systemic corticosteroids
|
Enhanced hypokalaemia risk; may potentiate hyperglycaemia | Monitor electrolytes and blood glucose |
|
Inhaled corticosteroids
|
Generally beneficial combination; minor hypokalaemia risk | Standard combination; monitor potassium with high doses |
|
Xanthines (theophylline)
|
Additive stimulatory effects; increased tremor, tachycardia | Monitor for adverse effects; may need dose adjustment |
|
Short-acting β2-agonists (salbutamol)
|
Additive cardiovascular effects with frequent rescue use | Acceptable for rescue; excessive SABA use indicates poor control |
|
Digoxin
|
Hypokalaemia from β2-agonist may increase digoxin toxicity | Monitor potassium and digoxin levels |
COMMON ADVERSE EFFECTS
- Tremor
- Palpitations
- Headache
- Local skin irritation at patch application site
- Insomnia or sleep disturbances
- Nervousness or restlessness
- Nausea
- Muscle cramps
SERIOUS ADVERSE EFFECTS
| Adverse Effect | Notes |
| Paradoxical bronchospasm | Discontinue immediately; provide alternative bronchodilator |
| Tachyarrhythmias (SVT, atrial fibrillation) | May require hospitalisation and drug discontinuation |
| Severe hypokalaemia | Monitor potassium; may precipitate arrhythmias |
| Severe skin hypersensitivity reactions | Remove patch immediately; discontinue drug; do not rechallenge |
| Anaphylaxis | Rare; requires immediate management and permanent discontinuation |
| Angina/myocardial ischaemia | In patients with underlying coronary artery disease |
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline
|
Heart rate, blood pressure, respiratory status, blood glucose (in diabetics), serum potassium (if on diuretics/corticosteroids), skin integrity at application sites |
|
After initiation (1–2 weeks)
|
Heart rate, tremor assessment, symptom control, skin site inspection |
|
Long-term
|
Periodic serum potassium (especially if on corticosteroids/diuretics), lung function testing (spirometry), reassessment of asthma/COPD control, skin condition at application sites |
BRANDS AVAILABLE IN INDIA
- Tulobro Patch (Cipla)
- Tulobron Patch (Zydus)
Note: Availability may vary regionally; primarily stocked at specialised respiratory centres and larger hospital pharmacies.
PRICE RANGE (INR)
| Formulation | Price Range | Notes |
| 0.5 mg patch | ₹25–₹35 per patch | Paediatric strength |
| 1 mg patch | ₹30–₹45 per patch | Paediatric/lower adult dose |
| 2 mg patch | ₹55–₹70 per patch | Standard adult dose |
- Not listed in NLEM India
- Price not NPPA-controlled
- Monthly cost (2 mg daily): approximately ₹1,650–₹2,100
CLINICAL PEARLS
- Maintenance only, not rescue — Tulobuterol patch is strictly for maintenance therapy; ensure all patients have a separate SABA rescue inhaler and understand the distinction.
- Always combine with ICS — Never prescribe tulobuterol monotherapy for asthma; LABA without inhaled corticosteroid is associated with increased mortality risk.
- Ideal for poor inhaler technique — Transdermal delivery is advantageous in paediatric patients, elderly, or those with cognitive/motor limitations who cannot use inhalers effectively.
- Evening application optimal — Applying patch in evening provides sustained bronchodilation through the night and early morning, addressing circadian variation in airway tone.
- Site rotation essential — Instruct patients to rotate application sites daily to prevent local skin reactions; avoid areas with cuts, irritation, or excessive hair.
- Monitor for cardiovascular effects — Despite transdermal route, systemic absorption occurs; be vigilant for tachycardia and palpitations, especially in elderly or cardiac patients.
TAGS
tulobuterol; LABA; long-acting beta-agonist; asthma maintenance; COPD; transdermal patch; bronchodilator; paediatric asthma; pulmonology; Schedule H
VERSION
RxIndia v0.9 — 28 Fb 2026
REFERENCES
- CDSCO approved product information
- Indian Pharmacopoeia / National Formulary of India
- NLEM 2022 (not listed)
- Indian Academy of Pediatrics (IAP) Guidelines for Management of Asthma
- API Textbook of Medicine
- AIIMS Drug Formulary
- Indian expert clinical practice protocols
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.